Non-Erosive Gastroesophageal Reflux Disease Clinical Trial
Official title:
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.
This is a multi-center, double blind, randomized, placebo-controlled, parallel-group, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (DWP14012 A mg or DWP14012 B mg or placebo). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00165646 -
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
|
Phase 3 | |
| Completed |
NCT02954848 -
Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
|
Phase 3 | |
| Completed |
NCT00165672 -
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
|
Phase 3 | |
| Completed |
NCT01047800 -
Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial
|
N/A | |
| Completed |
NCT01474369 -
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
|
Phase 3 |